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Abstract The purpose of our experiment was to examine
the influence of co-administration of nicotine and mephe-
drone on anxiety-like behaviors, cognitive processes and
the nicotine-induced behavioral sensitization as well as
processes connected with induction of oxidative stress in
the brain of male Swiss mice. The results revealed that co-
administration of subthreshold doses of mephedrone and
nicotine (0.05 mg/kg each) exerted marked anxiogenic
profile in the elevated plus maze and displayed pro-cog-
nitive action in the passive avoidance paradigm (nicotine
0.05 mg/kg and mephedrone 2.5 mg/kg). Furthermore, one
of the main findings of the present study was that mephe-
drone, administered alone at the dose not affecting loco-
motor activity of mice (1 mg/kg), enhanced the expression
of nicotine-induced locomotor sensitization. Moreover,
mephedrone administered with nicotine decreased general
antioxidant status and catalase activity as well as an-
tioxidant enzymes activity in the hippocampus and pre-
frontal cortex and increased concentration of malondi-
aldehyde, an indicator of lipid peroxidation processes.
Considering the likelihood that mephedrone is taken as a
part of polydrug combination with nicotine, the effects of
this combination on mammalian organisms have been
confirmed in our study. Understanding the consequences of
co-administration of psychoactive substances on the central
nervous system and oxidative processes in the brain pro-
vide the important toxicological significance, and may be
useful in polydrug intoxication treatment.
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Introduction
The use of different types of club drugs, especially by young
people, has been considered an ignored phenomenon for a
long time. Legal highs or club drugs, various kinds of products
containing psychoactive substances, were often taken as a part
of the nightclub scene with alcohol, marijuana or am-
phetamines. One such club drug is mephedrone (RS)-1-(4-
methylphenyl)-2-metyloaminopropan-1-one (other names:
4-metylometcatynon, 4-MMC, M-CAT), a synthetic deriva-
tive of cathinone [1].
Experienced users of mephedrone have equated its
powerful psychostimulant, entactogenic and hallucinogenic
properties to those of cocaine, amphetamine, or MDMA
(3,4-methylenedioxy-methamphetamine) [2, 3]. However,
only a few experimental studies have investigated its be-
havioral effects on laboratory animals. The first preclinical
studies of the effects of mephedrone, published by Kehr
et al. [4], reported significant, rapid and dose-dependent
increases in both serotonin (5-HT) and dopamine (DA)
levels in rats exposed acutely to this compound. This work
was extended by the finding that mephedrone causes a
rapid decrease in striatal DA and hippocampal 5-HT
transporters function. Furthermore, mephedrone inhibits
both synaptosomal DA and 5-HT uptake [5]. Recent
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preclinical findings point to its affinity for the serotonin-
ergic and the dopaminergic receptors [6] and capacity to
activate mesolimbic regions [7]. Moreover, several studies
have established a contradictory data concerning the neu-
rotoxic effect of mephedrone using a binge-like regimen.
Accordingly, Angoa-Pe´rez et al. [8–10] show that mephe-
drone does not cause damage of long lasting hippocampal
5-HT and DA nerve endings in mice and does not enhance
the effect of MDMA on 5-HT transporters (SERT) or
tryptophan hydroxylase 2 (TPH2). Therefore, Martı´nez-
Clemente et al. [6] observed loss of dopaminergic and
serotoninergic neurons. Additionally, it is well established
that psychostimulant drugs, including amphetamines or
cocaine, have been found to exert potent neurotoxic effects
due to their ability to increase the formation of reactive
oxygen and nitrogen species (ROS and RNS) as well as
intensification of lipids peroxidation processes [11]. How-
ever, little is still known about oxidative mechanisms of
mephedrone neurotoxicity.
Although mephedrone demonstrates a unique pharma-
cological profile, similarities in the mechanisms of action
among mephedrone and nicotine, a natural alkaloid present
in tobacco, can be observed. Nicotine exerts its effects
through activation of central nicotinic acetylcholine re-
ceptors (nAChR) [12]. These receptors are widely dis-
tributed in the central nervous system (CNS), and promote
the release of several neurotransmitters, such as acetyl-
choline (ACh), DA, noradrenalin, 5-HT and gamma-
aminobutiric acid (GABA) [12]. It is well documented that
nicotine exerts cognitive effects [13–15], analgesia [16],
and an influence on anxiety- [17], or depression-like be-
haviors [18]. The effects of nicotine have been extensively
investigated not only in humans, but also in animals and
several cell systems [19–24].
As mentioned above, mephedrone is often used in com-
bination with other substances, including nicotine, ethanol,
marijuana, amphetamines, cocaine and caffeine. However,
we observe the lack of experimental data concerning the
behavioral and biochemical effects relating to the combined
use of mephedrone with other psychoactive substances,
although the problem seems to be significant. There are
currently no studies describing the behavioral effects and
influence on oxidative stress processes of acute co-admin-
istration of mephedrone and nicotine. Thus, the present study
aimed to examine the interactions between mephedrone and
nicotine on memory consolidation processes observed in the
passive avoidance (PA) test. We also used the elevated plus
maze (EPM), a standard behavioral model that can assess
anxiety responses, after concomitant administration of both
drugs. Additionally, the present studies were undertaken to
investigate behavioral locomotor effects of these drugs. We
used the nicotine-induced locomotor sensitization procedure
evaluated in our previous studies [25] to examine if nicotine-
experienced mice developed hyper-reactivity to the loco-
motor stimulating effect of mephedrone. The total an-
tioxidant status (TAS), the activity of catalase (CAT), an
antioxidant enzyme, as well as concentration of malondi-
aldehyde (MDA) within the brain tissue were also deter-
mined to evaluate the general effects of mephedrone
administered alone or with nicotine on the antioxidant bar-
rier. Considering the likelihood that mephedrone is taken as a
part of polydrug combination with nicotine, knowledge
about drug interactions may be important in the treatment of
this kind of addiction.
Materials and Methods
Animals
The experiments were carried out on naive male Swiss
mice (Farm of Laboratory Animals, Warsaw, Poland)
weighing 20–25 g at the beginning of experiments. The
animals were maintained under standard laboratory con-
ditions (12 h light/dark cycle, room temperature
21 ± 1 C) with free access to tap water and laboratory
chow (Agropol, Poland) and were adapted to the laboratory
conditions for at least 1 week. Each experimental group
consisted of 8–10 animals. All experiments were conducted
according to the National Institute of Health Guidelines for
the Care and Use of Laboratory Animals and to the
European Community Council Directive for the Care and
Use of Laboratory Animals of 24 November 1986 (86/609/
EEC), and were approved by the local ethics committee.
Different mice were used for each drug and time treatment.
Drugs
The following compounds were tested: (-) nicotine hy-
drogen tartrate (0.05 and 0.5 mg/kg, Sigma-Aldrich, St.
Louis, MO, USA) and mephedrone [(RS)-2-methylamino-
1-(4-methylphenyl] propan-1-one, 0.05, 0.1, 0.25, 1, 2.5, 5
and 10 mg/kg; Toronto Research Chemicals Inc.,). Drugs
were dissolved in saline solution (0.9 % NaCl), nicotine
administered subcutaneously (s.c.) whereas mephedrone
was administered intraperitoneally (i.p.) at a volume of
10 ml/kg. Drug doses refer to the salt form. The pH of the
nicotine solution was adjusted to 7.0. Fresh drug solutions
were prepared on each day of experimentation. Control
groups received saline injections of the same volume and
via the same route of administration.
The doses of mephedrone and nicotine were chosen
based on literature data [26], our recently published articles
[27, 28] and preliminary studies.
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Experimental Procedure and Treatment
The EPM Procedure
The experimental apparatus was shaped like a ‘‘plus’’ sign
and consisted of a central platform (5 9 5 cm), two open
arms (30 9 5 cm) and two equal-sized enclosed
(30 9 5 9 15 cm) arms opposite to each other. The maze
was made of dark Plexiglas, elevated to a height of 50 cm
above the floor and illuminated by a dim light.
The used procedure was chosen based on our recently
published data [27, 28] and similar to the method of Lister
[29]. Anxiolytic activity was indicated by an increase in time
spent in the open arms or in the number of entries to the open
arms; anxiogenic effects were characterized by a decrease in
those measures. The percentage of time spent on the open
arms was calculated, just as was the percentage of entries into
the open arm. Additionally, the number of enclosed arm
entries was recorded as the indicator of motor activity of
tested animals. The mice were divided into following groups:
nicotine (0.05 mg/kg, s.c.), mephedrone (0.05, 0.1, 0.25, 1,
2.5, 5 and 10 mg/kg, i.p.), saline or mephedrone (0.05 mg/
kg, i.p.) co-administered with nicotine (0.05 mg/kg, s.c.)
The test was conducted 30 min after nicotine injection or
15 min after mephedrone administration.
The PA Procedure
The apparatus and PA procedure was described in detail in
our previous article [28]. It consisted of two-compartment
acrylic box with a lighted and darkened compartment. The
light chamber was illuminated by a fluorescent light (8 W)
and was connected to the dark chamber which was
equipped with an electric grid floor. Entrance of the animal
to the dark box was punished by an electric foot shock
(0.2 mA for 2 s).
On the first day of training (pre-test), mice were placed
individually into the light compartment and allowed to
explore the light box. After 30 s, the guillotine door was
raised to allow the mice to enter the dark compartment.
When the mice entered the dark compartment, the guil-
lotine door was closed and an electric foot-shock (0.2 mA)
of 2 s duration was delivered immediately to the animal.
The latency time for entering the dark compartment was
recorded (TL1). If the mouse failed to enter the dark box
within 300 s, it was placed into this dark box, the door was
closed, and the electric foot shock was delivered to the
animal. In this case, TL1 value was recorded as 300 s. In
the subsequent trial (retention) 24 h later, the same mouse
was again placed individually in the light compartment of
the PA apparatus and the time taken to reenter the dark
compartment was recorded (TL2). No foot-shock was ap-
plied in this trial. If the animal did not enter the dark
compartment within 300 s, the test was stopped and TL2
was recorded as 300 s.
The experimental procedure involved examination of
memory consolidation (the animals received injections of
the substance after pre-test) [30, 31].
During the acute treatment, animals were allocated into
the following drug groups: nicotine (0.05 mg/kg, s.c.),
mephedrone (1, 2.5, 5 mg/kg, i.p.), saline or mephedrone
(2.5 mg/kg, i.p.) co-administered with nicotine (0.05 mg/
kg, s.c.). The drugs were administered immediately after
pre-test (memory consolidation), and the mice were re-
tested 24 h later.
Influence of Mephedrone on the Expression of Nicotine-
Induced Locomotor Sensitization
This method was similar to that used in our previous ex-
periments accordingly to the data indicating that nicotine
produces robust locomotor sensitization in mice under our
laboratory conditions [25]. During the pairing phase (days
1–9), mice received injections of saline (s.c.) or nicotine
(0.5 mg/kg, s.c.) every other day for five sessions. The
mice remained drug free for 1 week and, on day 16, the
same groups of mice were further challenged with nicotine
(0.5 mg/kg), mephedrone (1 mg/kg) or saline, respectively.
Locomotor activity was recorded for 60 min during the
pairing phase (days 1–9) and on the 16th day, immediately
after injections. We have chosen the dose of mephedrone
not influencing the locomotor activity administered alone.
Collection of Tissues
Following the behavioral test conducted after repeated
administration of mephedrone, the mice were anesthetized,
decapitated and the whole brain was carefully taken out
and rinsed in isotonic saline to remove blood. The pre-
frontal cortex and the hippocampus were rapidly dissected
and were used for the study.
Preparation of Tissue Homogenates
The collected tissues were homogenized in 10 volumes of
20 mM Tris-HCl buffer (pH 7.4 on ice for 20 s) and cen-
trifuged at 12,0009g for 10 min at 4 C. The supernatant
was collected and used for further study. TAS, activity of
CAT, and MDA level were determined from these super-
natants spectrophotometrically with use of HITACHI 2800
apparatus and microplate reader EPOCH.
Determination of Malondialdehyde Concentration (MDA)
MDA was measured by the thiobarbituric acid (TBA) re-
action [32]. Briefly, 0.5 ml of tissue homogenate
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supernatant was mixed with 2.5 ml 1.22 M TCA in 0.6 M
HCl and allowed to stand for 15 min. Then 1.5 ml of 0.9 %
TBA was added and the mixture was incubated for 30 min
in a boiling water bath. After cooling, 4 ml of n-butanol
was added and the mixture was shaken variously. The
samples were centrifuged at 1500 g for 10 min and then
the absorbance of organic phase was measured at 532 nm
with respect to blank (n-butanol alone). The concentration
of MDA was read from the standard curve obtained by
using malonaldehyde bis-dimethylacetal and expressed as
lM of MDA/g of wet tissue.
Determination of Catalase Activity (CAT)
The activity of CAT in tissues homogenates was measured
with use of OxiSelect Catalase Activity Assay kit (Cell
Biolabs, San Diego, CA, USA). The assay was performed
following the manufacturer’s instructions. The absorbance
was read at 520 nm. Activities were calculated using a
calibration curve and were expressed as lM/min/mg
protein.
Determination of Total Antioxidant Status (TAS)
TAS of brain homogenates was determined with ready-to-
use diagnostic kit TAS by RANDOX (Randox Laboratories
Ltd., UK). The method assumes that ABTS [2,20-Azino-
di-(3-ethylbenzthiazoline sulphonate)] produces a radical
cation ABTS*? when incubated with a peroxidase (met-
myoglobin) and H2O2. The radical cation has a relatively
stable blue-green color, however its production can be
suppressed by the addition of antioxidants present in the
examined samples. Changes in absorption measured at
600 nm are proportional to the antioxidant concentration in
the tissues homogenates. Results are expressed in mM Fe/
ml tissue.
Statistical Analysis
The data were expressed as the mean ± standard error of
the mean (SEM). The statistical analyses were performed
by the two-way or one-way analysis of variance (ANOVA).
Post hoc comparison of means was carried out with the
Tukey’s test for multiple comparisons, when appropriate.
The confidence limit of p\ 0.05 was considered statisti-
cally significant.
For the memory related behaviors, changes in the PA
performance were expressed as the difference between
retention and training latencies and were taken as an index
of latency (IL). IL was calculated for each animal and
reports as the ratio:
IL ¼ TL2  TL1=TL1
TL1—the time taken to enter the dark compartment during
the training, TL2—the time taken to reenter the dark
compartment during the retention [33].
Results
Effects of Co-administration of Mephedrone
and Nicotine on Anxiety-Related Processes
in the EPM Test in Mice
Figure 1 shows that in animals which had received
mephedrone (0.05 mg/kg) in combination with nicotine
(0.05 mg/kg) significant effect was revealed on the per-
centage of open arm entries [two-way ANOVA: treatment
(F(1, 34) = 12.91, p\ 0.0010) and pre-treatment (F(1,
34) = 8.39, p\ 0.0066), without interactions effect (F(1,
34) = 0.91, p = 0.3469)] (Fig. 1a) as well as of time spent
on the open arms [two-way ANOVA: treatment (F(1,
33) = 11.69, p\ 0.0017) without interactions (F(1,
33) = 8.69, p\ 0.0591)] or pre-treatment effect [(F(1,
33) = 1.11, p = 0.2998)] (Fig. 1b). A post hoc analysis
showed that an acute dose of nicotine (0.05 mg/kg) and
mephedrone (0.05 mg/kg) alone did not affect the per-
centage of time spent on the open arms and of open-arm
entries. However, the post hoc Tukey’s test showed that co-
administration of mephedrone and nicotine at the inactive
doses decreased both values. Statistically significant de-
crease in open-arm entries was observed as compared with
nicotine-treated (p\ 0.05) and mephedrone-treated (p\
0.05) control groups (Fig. 1a). Also, statistically significant
decrease in percentage of time spent on the open arms was
observed as compared with nicotine-treated (p\ 0.05) and
mephedrone-treated (p\ 0.01) control groups (Fig. 1b).
Effects of Co-administration of Mephedrone
and Nicotine on Memory Related Behaviors
in the PA Test
Figure 2 indicates the effects of co-administration of ni-
cotine (0.05 mg/kg, s.c.) and mephedrone (2.5 mg/kg, i.p.)
on memory consolidation during the retention trial in the
PA task [two-way ANOVA: pre-treatment (F(1, 28) =
4.55, p = 0.0419), treatment (F(2, 28) = 20.47, p =
0.0001) and interactions (F(2, 28) = 8.82, p = 0.006)].
Statistically significant improvement in memory and
learning processes was observed in animals administered
with subthreshold doses of nicotine (0.05 mg/kg) and
mephedrone (2.5 mg/kg, see also Supplementary Fig. 7) in
combination with nicotine- or mephedrone-treated mice
(p\ 0.001 and p\ 0.01, respectively).
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Influence of Mephedrone on the Expression
of Nicotine-Induced Locomotor Sensitization
Two-way ANOVA of the locomotor response after ad-
ministration of nicotine (0.5 mg/kg, s.c.) or saline during
the pairing phase (day 1 and day 16—challenge) revealed a
treatment effect [F(4, 69) = 3.35, p\ 0.0111], a day effect
[F(1, 69) = 46.22, p\ 0.0001] and an interaction effect
[F(4, 69) = 7.95, p\ 0.0001] (Fig. 3). On the 1st day,
one-way ANOVA did not reveal any significant treatment
effect [F(1, 41) = 1.141, p = 0.3524]. On the 16th day,
after an additional injection of nicotine, one-way ANOVA
revealed a significant treatment effect [F(4, 32) = 9.236,
p\ 0.0001]. Indeed, after this last nicotine injection, a












































































































































Fig. 1 Mean (±SEM) percentage open arm entries (a) and percent-
age time spent on the open arms (b) in the EPM test in mice, 30 min
after an acute injection of saline, mephedrone (0.05 mg/kg, i.p.),
nicotine (0.05 mg/kg, s.c.), or mephedrone co-administered with
nicotine; n = 8–10; #p\ 0.05; ##p\ 0.01 versus mephedrone-treated
















































































Fig. 2 Effects of a co-administration of mephedrone (2.5 mg/kg,
i.p.), nicotine (0.05 mg/kg, s.c.) or saline on memory consolidation
trial using the PA test in mice. Appropriate groups of mice received
compounds immediately after the pre-test. Data represent the
mean ± SEM and are expressed as latency index (IL); n = 8–10;
^^^p\ 0.001 versus nicotine-treated control group; ##p\ 0.01 versus












































































Fig. 3 Effects of mephedrone (1 mg/kg, i.p.) on the expression of
locomotor sensitization to nicotine in mice. Nicotine (0.5 mg/kg, s.c.)
or saline were injected daily for 9 days, every other day; on day 16 (a
test for expression of sensitization) mice were given nicotine (0.5 mg/
kg), saline, or mephedrone (1 mg/kg). Data represent mean ± SEM;
n = 8–10 mice per group. &&&p\ 0.001 versus the first pairing day;
^^^p\ 0.001 versus saline-pretreated and nicotine-challenged mice;
##p\ 0.01 versus saline-pretreated and mephedrone-challenged mice;
Tukey’s test
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as compared to the 1st injection of nicotine (p\ 0.001) or
with the response to nicotine in animals repeatedly treated
with saline (p\ 0.001, Tukey’s test) (Fig. 3). Moreover,
mephedrone, at the dose of 1 mg/kg injected on the day 16
to the nicotine-pretreated group significantly increased the
locomotor activity of mice as compared to the first injec-
tion of nicotine (p\ 0.001) and to the group of animals
repeatedly treated with saline and challenged with
mephedrone (p\ 0.01, Tukey’s test). We have chosen the
dose of mephedrone not influencing the locomotor activity
administered alone as measured in the actimeter cages and
the EPM paradigm as the number of enclosed arm entries
(Supplementary Fig. 8; Supplementary Table 1).
Effects of Mephedrone on Oxidative Stress
Biomarkers
Effects of Co-administration of Mephedrone and Nicotine
on Oxidative Stress Indicators
The changes in value of TAS, activity of CAT and con-
centration of MDA were found after co-administration of
mephedrone and nicotine in the examined brain structures.
Figure 4 shows the activities of MDA after co-adminis-
tration of mephedrone and nicotine in the hippocampus
[two-way ANOVA: pre-treatment (F(1, 51) = 66.67
p\ 0.0001), and treatment (F(2, 51) = 10.30, p =
0.0001), without interaction effect (F(2, 51) = 0.32,
p = 0.7250)] and the prefrontal cortex [two-way ANOVA:
pre-treatment (F(1, 50) = 9.34, p = 0.0036) and treatment
(F(2, 50) = 9.17, p = 0.0004) without interaction effect
(F(2, 50) = 0.10, p = 0.9012)]. The post hoc Tukey’s test
revealed that an acute injection of mephedrone at the dose
of 2.5 mg/kg significantly increased level of MDA in the
hippocampus and prefrontal cortex (p\ 0.05) versus sal-
ine-treated control group. The same effects have been seen
after the dose of 5 mg/kg in both brain areas (Supple-
mentary Fig. 9). Also, nicotine (0.05 mg/kg) significantly
increased the concentration of the marker of lipids per-
oxidation processes in the prefrontal cortex (p\ 0.001).
Moreover, co-administration of nicotine (0.05 mg/kg) and
mephedrone in both used doses (0.05 and 2.5 mg/kg) led to
significant increase in MDA concentration in the prefrontal
cortex (nicotine ? mephedrone at the dose of 0.05 mg/
kg—p\ 0.001; nicotine ? mephedrone at the dose of
2.5 mg/kg—p\ 0.01) in comparison with appropriate
mephedrone-treated group.
Figure 5 shows the activities of CAT after co-adminis-
tration of mephedrone and nicotine in the hippocampus
[two-way ANOVA: pre-treatment (F(1, 50) = 21.82,
p\ 0.0001), and treatment (F(2, 50) = 7.94, p = 0.0001),
without interaction effect (F(2, 50) = 0.81, p = 0.4528)]
and the prefrontal cortex [two-way ANOVA: pre-treatment
(F(1, 50) = 16.14, p = 0.0002) and treatment (F(2,
50) = 7.36, p = 0.0017) without interaction effect (F(2,
50) = 0.97, p = 0.3851)]. The post hoc Tukey’s test re-
vealed that an acute injection of nicotine at the dose of
0.05 mg/kg significantly decreased the activity of CAT in
both examined structures (p\ 0.05) versus saline-treated
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Fig. 4 Effect of co-administration of mephedrone (0.05 or 2.5 mg/
kg, i.p.) and nicotine (0.05 mg/kg, s.c.) on concentration of MDA in
the hippocampus and prefrontal cortex of mice. Data are presented as
the mean ± SEM; n = 8–10; *p\ 0.05; ***p\ 0.001 versus saline-
treated control group; ^^p\ 0.01 versus mephedrone 2.5 mg/kg-
treated control group; &&&p\ 0.001 versus mephedrone 0.05 mg/kg-
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Fig. 5 Effect of co-administration of mephedrone (0.05 or 2.5 mg/
kg, i.p.) and nicotine (0.05 mg/kg, s.c.) on activity of CAT in the
hippocampus and prefrontal cortex of mice. Data are presented as the
mean ± SEM; n = 8–10; *p\ 0.05; **p\ 0.01 versus saline-treat-
ed control group; ^p\ 0.05 versus mephedrone 2.5 mg/kg-treated
control group; &p\ 0.05 versus mephedrone 0.05 mg/kg-treated
control group; #p\ 0.05 versus nicotine-treated control group;
Tukey’s test
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decreased the activity of the enzyme in the hippocampus
and prefrontal cortex (p\ 0.01) (see also the same effects
for the dose of 5 mg/kg, Supplementary Fig. 10). More-
over, co-administration of nicotine (0.05 mg/kg) and
mephedrone (0.05 mg/kg) significantly deceased CAT ac-
tivity in the hippocampus (p\ 0.05) in comparison to
mephedrone–treated group. Furthermore, significant de-
crease in CAT level was observed in the hippocampus
when mephedrone (2.5 mg/kg) was co-administered with
nicotine versus mephedrone-treated mice (p\ 0.05) as
well as in the prefrontal cortex (p\ 0.05) versus nicotine-
treated mice.
Figure 6 shows the values of TAS after co-administra-
tion of mephedrone and nicotine in the hippocampus [two-
way ANOVA: treatment (F(2, 54) = 11.54, p\ 0.0001)
without pre-treatment (F(1, 54) = 1.46, p = 0,2300), and
interaction effect (F(2, 54) = 0.01, p = 0.9960)] and the
prefrontal cortex [two-way ANOVA: pre-treatment (F(1,
54) = 33.15, p\ 0.0001) and treatment (F(2, 54) = 4.54,
p = 0.0150) without interaction effect (F(2, 54) = 0.52,
p = 0.5992)]. The post hoc Tukey’s test revealed that an
acute injection of nicotine at the dose of 0.05 mg/kg sig-
nificantly decreased TAS values in the prefrontal cortex
(p\ 0.01) versus saline-treated control group. Also,
mephedrone (2.5 mg/kg) significantly decreased the con-
centration of antioxidants in the hippocampus (p\ 0.05)
(see also the same effects of the dose of 5 mg/kg in both
structures, Supplementary Fig. 11). Moreover, co-admin-
istration of nicotine (0.05 mg/kg) and mephedrone
(2.5 mg/kg) led to significant decrease in TAS value in the
hippocampus (p\ 0.01) and prefrontal cortex (p\ 0.05)
in comparison with nicotine-treated group. Furthermore,
significant decrease in TAS level was also observed when
mephedrone (2.5 mg/kg) was co-administered with ni-
cotine in the prefrontal cortex (p\ 0.01) versus mephe-
drone-treated mice.
Discussion
This study attempts for the first time to show the acute,
behavioral effects of mephedrone and nicotine co-admin-
istration using animal experimental models. In addition, we
assessed the effect of the combined administration of
mephedrone and nicotine on oxidative status in the brain.
Our results showed that animals treated with mephedrone
and nicotine at the subthreshold doses demonstrated
elevated level of anxiety in the EPM test and displayed pro-
cognitive behaviors in the PA paradigm. Also, the results
confirmed that repeated daily injections of nicotine pro-
duced progressive increases in locomotor activity in mice,
especially to a subsequent nicotine challenge. One of the
main findings of the current study was that mephedrone,
administered at the dose not influencing the locomotor
activity of mice, enhanced the expression of nicotine-in-
duced sensitization. Indeed, nicotine-experienced mice
showed an increased response to the mephedrone injection
compared with both the first pairing day and the response
to acute mephedrone challenge in animals pre-exposed to
saline. Additionally, our results indicated that mephedrone
as well as nicotine exerted strong pro-oxidative effects.
First, the research proved a decrease in total antioxidant
status, i.e., general concentrations of all antioxidant
molecules present in the samples of the hippocampus and
the prefrontal cortex. Then, decrease in CAT activity
confirmed that the oxidative action of the drugs was as-
sociated with overproduction of reactive oxygen species;
here H2O2, as CAT is involved in hydrogen peroxide dis-
integration to water and oxygen. Finally, an increase in
MDA concentration revealed induction of oxidative dam-
ages to brain lipids. Additionally, co-administration of both
psychoactive substances intensified the oxidative changes
in particular structures of the brain.
Many of the available studies indicate that amphetami-
nes increase neuropsychiatric symptoms like anxiety in
animal models as well as humans [34–37]. On the other
hand, den Hollander et al. [38] observed that anxiety- and
depression-related behaviors did not appear after mephe-
drone administration using binge like regimen. However,
our studies revealed that this compound administered alone
exerted a strong anxiogenic action in the dose range of
0.25–10 mg/kg, but the dose of 0.05 mg/kg did not influ-
ence the observed effect.
Our previous results have shown that a single injection
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Fig. 6 Effect of co-administration of mephedrone (0.05 or 2.5 mg/
kg, i.p.) and nicotine (0.05 mg/kg, s.c.) on activity of TAS in the
hippocampus and prefrontal cortex of mice. *p\ 0.05; **p\ 0.01
versus saline-treated control group; ^^p\ 0.01 versus mephedrone
2.5 mg/kg-treated control group; #p\ 0.05; ##p\ 0.01 versus ni-
cotine-treated control group; Tukey’s test
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anxiogenic effect in the EPM test [27], whereas the dose of
0.05 mg/kg of nicotine did not statistically change the
values of time spent in open arms and number of entries
into the enclosed arms of the maze [28]. In the present
experiments, when mephedrone and nicotine were co-ad-
ministered at the nonactive doses, a powerful anxiogenic
effect was observed. Mice treated with both drugs spent
less time in the open arms and presented a lower percent-
age of entries into enclosed arms of EPM test. Entries into
enclosed arms increased only in groups treated with
mephedrone alone at the doses of 2.5, 5 and 10 mg/kg,
suggesting that motor effects are not the cause of the
anxiogenic response.
The pathogenesis of anxiety is associated with deviation
in release of different neurotransmitters, and engages a
variety of brain structures. It is well established that neu-
ronal system such as cholinergic, adrenergic, dopaminer-
gic, GABA-ergic, serotoninergic and glutamatergic [12]
play roles in anxiety processes. As stated previously,
mephedrone increases extracellular DA, 5-HT and nora-
drenalin level in the CNS [4, 5]. Also, activation of the
nAChRs by nicotine enhances the release of many neuro-
transmitters, including DA, ACh, noradrenalin, glutamate
and 5-HT involved in the anxiety modulation of drugs [12].
We may suspect that enhancing of anxiety level observed
in our experiments may be dependent on severity of
monoamine transmission after co-administration of both
drugs. However, on the basis of our biochemical studies we
may also suggest that anxiety-like behaviors are not asso-
ciated with oxidative damage in the CNS. Co-administra-
tion of low doses of both drugs increased only MDA level
in the prefrontal cortex and decreased CAT activity in the
hippocampus without influence on the other measured
parameters.
Moreover, very strong anxiogenic activity of mephe-
drone was observed in the EMP test. 50-fold and tenfold
lower doses (0.1 and 0.25 mg/kg) were active in this test
than in the PA paradigm. We can not exclude that this
difference in the effectiveness may be due to a local non-
specific irritant effect of administered mephedrone by in-
traperitoneal injections. It is known that repeated intra-
venous injections of mephedrone in humans (even only 2–3
times) lead to local necrotic lesions. For this reason, human
administration is normally oral, nasal or rectal [1–3].
Another aim of the present research was to record the
interaction between mephedrone and nicotine at the level
of cognitive processes at the consolidation trial, using the
PA test in mice. Evidences show that memory deficits
occurs after chronic use of psychostimulants, and the
neurodegenerative effects of these compounds may lead to
cognitive disabilities [39, 40]. Recent research also indi-
cates that chronic or subchronic administration of mephe-
drone causes a reduction in memory function in rats [7, 38,
41]. However, other data indicate that mephedrone in-
creases cognitive function after an acute administration
similarly to other stimulants [42]. Also, series of study
show that a post-training injection of d-amphetamine im-
proves memory storage processes in the consolidation
phase [43]. Our studies correspond with these results, as an
acute administration of mephedrone, at the highest dose
(5 mg/kg), improved memory processes in the consolida-
tion trial. In animals, step-through latency to enter the dark
compartment was significantly longer in the 24 h test,
showing that they remembered the training session. Fur-
thermore, in the current study we revealed that co-admin-
istration of subthreshold doses of mephedrone and nicotine
produced an improvement in the memory processes in
animals during the consolidation phase.
It is also well known that nicotine induces cognitive
effects [44–46]. According to the previous study, we chose
the subthreshold dose of nicotine (0.05 mg/kg) which has
not affected memory and learning processes [28]. It should
be noted that experiments with post-training drug admin-
istration have provided strong evidence that the memory
enhancing effect of the drug is not a consequence of in-
fluences on acquisition processes or performance, because
rodents are drug-free during the pre-test and test [47, 48].
Moreover, when the consolidation processes are measured,
the stimulation of locomotor activity by mephedrone at the
dose 5 mg/kg does not affect the obtained result.
Two anatomic structures have been recognized as im-
portant players in memory consolidation, e.g., the hip-
pocampus and neocortex. These processes are mediated
mainly by NMDA receptor activation and by dopaminergic
systems [49, 50]. Additionally, GABA, noradrenalin, and
5-HT are also involved in the memory modulation [12, 51].
The neurobiological mechanisms of cognitive-enhance-
ment by nicotine are well-characterized, and among all
central nAChR subtypes, both the a4b2 combination and
the a7 subunits appear to play important roles in memory-
related responses [52]. The prefrontal cortex and the hip-
pocampus seem to be important target sites for the nicotine
effects on memory function [53, 54]. It is possible to
suggest that the synergistic effect of an acute administra-
tion of nicotine and mephedrone on cognitive processes
observed in our experiments may be explained by the in-
fluence of both drugs on dopaminergic and serotoninergic
neurotransmission in the brain. Unfortunately, previously
mentioned brain structures, e.g., hippocampus and pre-
frontal cortex are very susceptible to oxidative damage.
Generally, a lot of evidence exists that intensification of
oxidative processes is the primary cause of neurodegen-
eration. Indeed, mephedrone administered alone at the
higher doses (2.5 and 5 mg/kg) as well as co-administra-
tion of mephedrone and nicotine induced oxidative stress
observed as an increase in MDA levels and a decrease in
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TAS values and CAT activity in both structures. Therefore,
we could expect impairment of memory processes. How-
ever, mephedrone-induced oxidative stress may not be long
lasting, taking into consideration strong defense mechan-
isms of healthy organisms of experimental animals, as in
the experiment only single doses of the drug were used. It
shows proper functioning of an antioxidant system, which
consists of low-molecular weight endogenous antioxidants,
antioxidant proteins and enzymes as well as many regulator
proteins that mediate adaptive responses to oxidative stress
[55]. Therefore, such a one-time pro-oxidative intervention
may stimulate antioxidant barrier to enhance release of
intracellular antioxidants as well as up-regulation of ROS-
metabolizing enzymes expression to counteract similar
episodes in future. In our experiments, the memory pro-
cesses were investigated 24 h after drug injection, when we
did not observe changes in antioxidant status of brain tissue
(data not shown). The attempts to understand the
mechanisms underlying adaptive cell responses to mephe-
drone as well as nicotine-induced oxidative stress will
provide new insight into development of neuroprotective
treatment among psychoactive drug users and effective
strategies for withdrawal therapy.
Furthermore, behavioral sensitization observed in our
experiments, refers to a phenomenon by which the repeated
use of a drug produces a progressive increase in the psy-
chomotor response and has been implicated in the develop-
ment of drug addiction [56–59] and drug-induced psychosis
[60]. Behavioral sensitization can persist for several weeks
and results from neuroplasticity in mesolimbic dopaminer-
gic pathways [58, 61, 62]. Several drugs have been found to
induce behavioral sensitization including cocaine, am-
phetamine, opiates [62] and nicotine [63]. It has been shown
that repeated treatment with an addictive drug produces
cross-sensitization defined as hyper-responsiveness to one
psychostimulant after pre-exposure to a different drug [56,
64–66]. We used the nicotine-induced locomotor sensitiza-
tion procedure to examine if nicotine-experienced mice
show hyperactivity after an acute mephedrone administra-
tion. Our results confirmed that repeated daily injections of
nicotine produced progressive increases in locomotor ac-
tivity in mice, especially to a subsequent nicotine challenge
[35, 67, 68]. Experimental data show that the expression of
both acute and sensitizing locomotor effects of nicotine
is coincident with functional changes in mesolimbic
dopaminergic neurotransmission [69]. Concerning mephe-
drone, this drug induces short-term hyperlocomotion due to
increased DA and endogenous 5-HT levels [4, 26, 70]. One
of the main findings of the present study was the develop-
ment of locomotor hyperactivity to mephedrone in nicotine-
sensitized mice. We can’t exclude the existence of the full
cross-sensitization phenomenon between nicotine and
mephedrone, due to their similar neural pathways affected,
but studies concerning the ability of mephedrone to elucidate
behavioral sensitization are still unexplored and further
analysis are needed.
In summary, abuse of psychoactive drugs constitutes a
major problem worldwide, especially among young adults.
The structural similarities of methcathinone and methylone
with mephedrone suggest that we may still not appreciate
the long-term risks of mephedrone use. There is also a
great tendency for drug users to engage in simultaneous
poly-substance use. Thus, polydrug use may be the rule
rather than exception. Our study has shown the existence of
strong interaction after an acute, concomitant administra-
tion of nicotine and mephedrone in anxiety, memory and
locomotor sensitization experimental paradigms. Co-ad-
ministration of subthreshold doses of both drugs exerts an
anxiogenic effect and memory improvement. Both sub-
stances, mephedrone and nicotine, have been found to exert
strong pro-oxidant effect on brain tissue. This influence
was even stronger when both drugs were administered to-
gether. Finally, locomotor hyperactivity between nicotine
and mephedrone when mice were pretreated with nicotine
was obtained. Understanding the consequences of co-ad-
ministration of psychoactive substances on the CNS and
oxidative processes in the brain provide the toxicological
significance, and may be useful in polydrug intoxication
treatment. However, further research is required to deter-
mine long-term effects of mephedrone.
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